Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and External Validation of a Machine Learning Model for 10-Year Ischemic Stroke Risk Prediction in Diverse Populations.

medRxiv : the preprint server for health sciences·2026
Same author

Where risk becomes visible: a layered fixed-policy framework for diabetic kidney disease screening in type 2 diabetes.

medRxiv : the preprint server for health sciences·2026
Same author

Four Consecutive False Negative Newborn Screens in a Patient with Classical Congenital Adrenal Hyperplasia: A Case Report

Journal of clinical research in pediatric endocrinology·2026
Same author

Development and validation of a two-stage machine learning model for personalised type 2 diabetes screening in the All of Us Research Program and UK Biobank.

BMJ open·2026
Same author

A 7-year experience in adenoidectomy with endoscopic radiofrequency volume reduction.

Scientific reports·2025
Same author

Optimizing glucocorticoid therapy in congenital adrenal hyperplasia and analog conditions: the intersection of dose reduction, patient care, and coverage in the US.

Frontiers in endocrinology·2025

Related Experiment Video

Updated: Apr 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Double device left atrial appendage closure.

Ênio E Guérios1, Steffen Gloekler, Michael Schmid

  • 1Department of Cardiology, Bern University Hospital, Bern, Switzerland.

Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
|July 11, 2014
PubMed
Summary
This summary is machine-generated.

Dual device implantation for left atrial appendage (LAA) occlusion is a feasible strategy for patients with non-valvular atrial fibrillation (NVAF) experiencing incomplete closure with a single device, showing favorable long-term outcomes.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K

Related Experiment Videos

Last Updated: Apr 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.3K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Percutaneous left atrial appendage (LAA) occlusion offers an alternative to oral anticoagulation for stroke prevention in non-valvular atrial fibrillation (NVAF).
  • Anatomical variations in the LAA can challenge complete occlusion with a single device.

Observation:

  • In 5 of 223 patients, a second device was implanted due to significant residual leaks or uncovered LAA portions after initial percutaneous LAA occlusion.
  • Various device combinations were used, including AMPLATZER Cardiac Plugs (ACP), AMPLATZER Vascular Plugs, and AMPLATZER Septal Occluders (ASO).

Findings:

  • All procedures were successful without complications.
  • Transesophageal echocardiography (TOE) at follow-up confirmed complete LAA closure in all patients, with no device-related thrombus.
  • Over 14 patient-years, no strokes, peripheral thromboemboli, or device embolizations occurred.

Implications:

  • Implanting two devices for LAA occlusion is a feasible and effective strategy when a single device is insufficient.
  • This approach may expand indications for LAA occlusion to include patients with large or complex LAA anatomies.